AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
alvimopan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 143 | 156053-89-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 2 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.81 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 6 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.43 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 5.84 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.20 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 5.30 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 0.226 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 4.395 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.596 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 4.677 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 22.460 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 18.740 | % | High | 1 |
| herg | hERG pIC50 | 4.817 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 3.381 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 5.521 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 24.700 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK,TGFBR1,ZAP70 | 25 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,EIF2AK3,EPHB4,GRK2,MAP2K6,PIK3CD,TEK,TGFBR1 | 10 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.535 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 26.792 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 23.770 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 2.014 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 26.910 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 15.524 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 79.740 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 24.280 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 901.571 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 20, 2008 | FDA | CUBIST PHARMS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A06AH02 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR CONSTIPATION DRUGS FOR CONSTIPATION Peripheral opioid receptor antagonists |
| FDA MoA | N0000000154 | Opioid Antagonists |
| MeSH PA | D005765 | Gastrointestinal Agents |
| FDA EPC | N0000175691 | Opioid Antagonist |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50503 | laxative |
| CHEBI has role | CHEBI:55324 | gastrointestinal drug |
Related Drugs by ATC class:
A06AH Peripheral opioid receptor antagonists 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postoperative ileus | indication | 235833007 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Hepatic failure | contraindication | 59927004 | |
| Chronic renal failure syndrome | contraindication | 90688005 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.38 | acidic |
| pKa2 | 9.82 | acidic |
| pKa3 | 9.22 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 12MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ENTEREG | CUBIST PHARMS | N021775 | May 20, 2008 | DISCN | CAPSULE | ORAL | 8946262 | Feb. 12, 2030 | A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Mu-type opioid receptor | GPCR | ANTAGONIST | Ki | 9.40 | WOMBAT-PK | CHEMBL | |||
| Kappa-type opioid receptor | GPCR | Ki | 7 | CHEMBL | |||||
| Delta-type opioid receptor | GPCR | Ki | 7.92 | CHEMBL | |||||
| Kappa-type opioid receptor | GPCR | Ki | 8.30 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4025232 | VUID |
| N0000179783 | NUI |
| D02878 | KEGG_DRUG |
| 170098-38-1 | SECONDARY_CAS_RN |
| 1516803 | RXNORM |
| C1508750 | UMLSCUI |
| CHEBI:135686 | CHEBI |
| NG0 | PDB_CHEM_ID |
| CHEMBL270190 | ChEMBL_ID |
| DB06274 | DRUGBANK_ID |
| C419502 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5488548 | PUBCHEM_CID |
| 7471 | IUPHAR_LIGAND_ID |
| 677C126AET | UNII |
| 136917 | MMSL |
| 25351 | MMSL |
| 341264 | MMSL |
| d07141 | MMSL |
| 8245 | INN_ID |
| 4025232 | VANDF |
| 012792 | NDDF |
| 437886007 | SNOMEDCT_US |
| 437917007 | SNOMEDCT_US |
| 677C126AET | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Alvimopan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0668 | CAPSULE | 12 mg | ORAL | ANDA | 25 sections |
| ALVIMOPAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0254-3012 | CAPSULE | 12 mg | ORAL | ANDA | 26 sections |
| Alvimopan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2312 | CAPSULE | 12 mg | ORAL | ANDA | 26 sections |
| Alvimopan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-870 | CAPSULE | 12 mg | ORAL | ANDA | 25 sections |